Mirvetuximab
As of the edition of 20 October 2026, Mirvetuximab is an antibody: marketed, first approved in 2025 (CH); acts on FOLR1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2025
- Kind
- Antibody
- Brand name
- Elahere
- First approved
- 13 March 2025 (CH)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- AbbVie
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| FOLR1 | Folate receptor alpha | P15328 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| AbbVie | Applicant | 2025 to now |